The proposed PCBERT-GAT-DFFNN-DTA model, a three-stage deep cross-modal representation fusion framework for accurate DTA prediction, achieves significant improvements in R2 scores across all datasets, demonstrating its effectiveness in learning complex drug protein interactions for reliable DTA prediction.
Abstract
Prediction of Drug Target Affinity (DTA) is essential for accelerating computational drug discovery and reducing experimental costs. However, traditional experimental approaches for DTA estimation are resource-intensive and are further challenged by the structural flexibility of both drugs and target proteins. In this work, we propose the PCBERT-GAT-DFFNN-DTA model, a three-stage deep cross-modal representation fusion framework for accurate DTA prediction. In the first stage, variable-length protein sequences are transformed into contextual representations using ProtBERT to obtain fixed-size protein embeddings. Drug molecules are represented using two modalities: sequence-based embeddings generated from ChemBERT and structure-based embeddings learned from molecular graphs using a Graph Attention Network (GAT). In the second stage, each modality is processed through dedicated subnetworks to refine features and reduce dimensionality while preserving modality-specific information. In the final stage, the refined representations are fused and passed to a Deep Feed-Forward Neural Network (DFFNN) to predict drug target binding affinity. The proposed model consistently outperformed most baseline methods under the S1-S3 evaluation settings across the benchmark datasets. Under the more challenging S4 blind setting, the model achieved strong performance on the KIBA dataset and competitive results on the Davis and Metz datasets. Compared with LLMDTA, the proposed approach achieves significant improvements in R2 scores across all datasets, demonstrating its effectiveness in learning complex drug protein interactions for reliable DTA prediction.
The proposed MAGNN-DTA employs a cross-modal mutual attention module to explicitly capture bidirectional interactions between drug and protein modalities, enabling precise identification of key functional groups in drugs and critical binding residues in proteins.
Yun Zhou, Yi-Bo Zhang, Dong Liu et al.· IEEE Transactions on Computa...· 0 citations
Drug-target affinity prediction provides a computational basis for virtual screening and drug repositioning optimization by estimating the binding strength between compounds and target proteins. Existing deep learning methods have evolved from early SMILES/amino acid sequence modeling to graph neural networks and multi...
Yu-Ning Liu, Guang-Ze Wang, Dan Liu et al.· European journal of medicina...· 0 citations
EQTri-DTI is designed to integrate three modality-specific networks to encode 1D protein sequences, 2D molecular images, and 3D drug structures and develops a joint uncertainty quantification scheme by calculating the weight summation of evidential uncertainty and prediction entropy from the aforementioned output, enab...
A two-stage contrastive learning framework integrating drug structures, protein sequences, and Cell Painting morphological profiles into a unified embedding space, which reveals pathway-specific morphological signatures associated with drug targets, providing biologically interpretable insights into drug mechanisms.
Experimental results on multiple benchmark data sets demonstrate that MMU-DPI outperforms several state-of-the-art DPI prediction methods and indicate that MMU-DPI can serve as a useful computational tool for drug discovery.
Jia-Hao Wei, Tie Shen· Journal of Chemical Informat...· 0 citations
Results indicate simple architectural modifications to traditional convolution methods may be sufficient to bridge the gap to large pre-trained PLMs, and an architectural modification of the baseline convolution method designed to improve protein representation learning is evaluated.
Matija Marijan, Ivan Tanasijević· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.